XML 61 R49.htm IDEA: XBRL DOCUMENT v3.26.1
Liability Related to the Revenue Participation Right (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2026
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Other Commitments [Line Items]          
Non-cash interest expense related to revenue participation right liability     $ 5,941,000 $ 0  
Royalty Pharma | Royalty Agreement          
Other Commitments [Line Items]          
Authorized funding         $ 275,000,000.0
Royalty rate         9.25%
Proceeds received $ 200,000,000.0        
Additional payment         $ 75,000,000.0
Initial investment proceeds multiple, maximum         3.0
Initial investment proceeds multiple, minimum         2.5
Transaction costs $ 400,000        
Annual interest rate   12.00% 12.00%    
Non-cash interest expense related to revenue participation right liability   $ 5,900,000      
Payments for royalties   $ 0 $ 0